RecruitingPhase 3NCT06891443
Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)
Studying Leber congenital amaurosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Laboratoires Thea
- Intervention
- sepofarsen(drug)
- Enrollment
- 32 enrolled
- Eligibility
- 6 years · All sexes
- Timeline
- 2025 – 2028
Study locations (14)
- UCSF Wayne and Gladys Valley Center for Vision, San Francisco, California, United States
- University of Miami - Bascom Palmer Eye Institute, Miami, Florida, United States
- University of Iowa, Iowa City, Iowa, United States
- University of Minnesota Medical School, Minneapolis, Minnesota, United States
- University of Pennsylvania - Center for Advanced Retinal & Ocular Therapeutics, Philadelphia, Pennsylvania, United States
- Universitair Ziekenhuis Gent (UZ), Ghent, Belgium
- University of Alberta, Edmonton, Alberta, Canada
- The Hospital for Sick Children - SickKids, Toronto, Ontario, Canada
- Centre de maladies rares CHNO des Quinze Vingt, Paris, France
- Justus-Liebig Universität - Department of Ophthalmology, Giessen, Germany
- Klinikum der Ludwig-Maximilian Universität München, München, Germany
- University of Tuebingen - Inst. for Ophthalmic Research, Tübingen, Germany
- Radboud Universitair Medisch Centrum, Nijmegen, Netherlands
- Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom
Collaborators
Sepul Bio
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06891443 on ClinicalTrials.govOther trials for Leber congenital amaurosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT05906953Safety and Efficacy Trial of HG004 for Leber Congenital Amaurosis Related to Rpe65 Gene Mutations (STAR)HuidaGene Therapeutics Co., Ltd.
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT06088992Leber Congenital Amaurosis Inherited Blindness of Gene Therapy Trial(LIGHT)Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT03920007Study of Subretinally Injected ATSN-101 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2DAtsena Therapeutics Inc.
- ACTIVE NOT RECRUITINGPHASE2, PHASE3NCT03913143A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE)ProQR Therapeutics
- ACTIVE NOT RECRUITINGPHASE3NCT00999609Safety and Efficacy Study in Subjects With Leber Congenital AmaurosisSpark Therapeutics, Inc.
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT01208389Phase 1 Follow-on Study of AAV2-hRPE65v2 Vector in Subjects With Leber Congenital Amaurosis (LCA) 2Spark Therapeutics, Inc.